Table 3. Meta-analysis results of the associations of p62 expression with clinicopathological parameters.

Clinicopathological parameter	Ref	Overall OR (95% CI)	Heterogeneity test (I2, P-value)
Gender (male vs female)	[16, 17, 19, 21, 23, 31, 35]	1.00 (0.78–1.29)	0.0%, 0.663
Tumor Differentiation (poor VS well)	[16, 17, 19, 20, 29–32]	0.86 (0.67–1.11)	71.8%, 0.001
Tumor Size (T3-4 vs T1-2)	[17, 20, 23, 27, 29, 30, 32, 33, 35]	1.13 (0.96–1.33)	60.6%, 0.009
Lymph Node Metastasis (yes vs no)	[16, 19, 20, 27, 29–33]	1.21 (1.06–1.37)	78.6%, < 0.001
Clinical Stage (III-IV vs I-II)	[16, 17, 19–21, 23, 24, 27, 29–31, 33, 35]	127 (1.12–1.45)	84.3%, < 0.001